BUZZ-Apogee Therapeutics soars on report Abbvie nearing $11 bln buyout deal

Apogee Therapeutics, Inc.
AbbVie, Inc.

Apogee Therapeutics, Inc.

APGE

0.00

AbbVie, Inc.

ABBV

0.00

** Shares of drug developer Apogee Therapeutics APGE.O jump 54.4% to $139.5 premarket

** Abbvie ABBV.N nearing deal to buy APGE for $10.9 bln in cash, Financial Times reported on Friday

** Deal would value the drug developer at roughly 60% premium to Thursday's close - report

** As of last close, APGE market cap was at $6.8 bln - LSEG data

** APGE secured $1.3 bln financing deal from Blackstone for experimental eczema drug

** As of last close, APGE stock was up 19.7% YTD


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.